ABVC BioPharma Secures Patent in Japan for Depression Treatment ABV-1504
TL;DR
ABVC BioPharma secures new patent for MDD treatment, strengthening global IP portfolio and enhancing market competitiveness.
ABVC's ABV-1504, derived from Polygala tenuifolia, acts as a NET inhibitor, offering a safer, non-addictive long-term treatment for MDD.
ABV-1504 aims to provide a safer, non-addictive, and better-tolerated long-term treatment for individuals suffering from depression, making the world a better place.
Japan Patent Office grants new patent protection for ABV-1504, enhancing ABVC's global IP portfolio and market presence in the pharmaceutical industry.
Found this article helpful?
Share it with your network and spread the knowledge!
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced the Japan Patent Office's grant of a new patent for its Major Depressive Disorder (MDD) candidate, ABV-1504. This patent, valid through 2040, enhances ABVC's global intellectual property portfolio for PDC-1421, the active botanical ingredient in ABV-1504, now protected in four major territories including the United States, Australia, Japan, and Taiwan.
The global antidepressant market is projected to reach $20 billion by 2030, with MDD affecting over 280 million people worldwide. ABV-1504, derived from Polygala tenuifolia, offers a botanical-based alternative to traditional SSRIs, acting as a Norepinephrine Transporter (NET) inhibitor. It has shown favorable safety and efficacy in Phase II clinical studies, aiming to provide a safer, non-addictive treatment for depression.
In November 2023, ABVC entered a $667 million global licensing agreement with AiBtl BioPharma Inc. for ABV-1504 and ABV-1505 (ADHD), receiving 46 million AiBtl shares and eligibility for up to $7 million in milestone-based cash payments. Upon commercialization, ABVC will receive 5% royalties on net sales, up to $200 million, highlighting the commercial potential of its botanical CNS pipeline.
Japan's antidepressant market, expected to reach $1.25 billion by 2025, presents a favorable environment for ABV-1504, given the country's history of integrating botanical-based medicines like Kampo. ABVC's strategic presence in Japan through BioLite Japan K.K., a joint venture, facilitates market expansion and commercialization planning, leveraging Japan's advanced pharmaceutical market and regulatory framework.
Dr. Uttam Patil, ABVC Chief Executive Officer, stated, 'Securing patent protection in Japan further validates the innovation behind our botanical drug platform.' With strong IP protection and a global licensing deal, ABV-1504 is poised to compete internationally and deliver long-term shareholder value.
For more information on the antidepressant market, visit https://www.alliedmarketresearch.com/antidepressants-drugs-market?utm_source=chatgpt.com. Details on Japan's mental health market can be found at https://www.statista.com/outlook/hmo/mental-health/depressive-disorders/japan and https://www.statista.com/topics/8609/mental-health-in-japan/#topicOverview.
Curated from NewMediaWire
